Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Department of Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA.
Department of Orthopedic Surgery, The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Brigham and Women's Hospital, Boston, MA.
Semin Arthritis Rheum. 2018 Oct;48(2):205-213. doi: 10.1016/j.semarthrit.2018.01.002. Epub 2018 Jan 8.
Hydroxychloroquine (HCQ) is the standard of care medication for most SLE patients, however nonadherence is common. We investigated longitudinal patterns and predictors of nonadherence to HCQ in a U.S. SLE cohort of HCQ initiators.
We used Medicaid data from 28 states to identify adults 18-65 years with prevalent SLE. We included HCQ initiators following ≥6 months without use, and required ≥1 year of follow-up after first dispensing (index date). We used the proportion of days covered (PDC) to describe overall HCQ adherence (<80% = nonadherent) and novel group-based trajectory models (GBTM) to examine monthly patterns (<80% of days/month covered = nonadherent), during the first year of use. Multivariable multinomial logistic regression models were used to examine predictors of nonadherence.
We identified 10,406 HCQ initiators with SLE. Mean age was 38 (±12) years, 94% were female, 42% black, 31% white; 85% had a mean PDC < 80%. In our 4-group GBTM, 17% were persistent adherers, 36% persistent nonadherers, and 47% formed two dynamic patterns of partial adherence. Adherence declined for most patients over the first year. Compared to persistent adherers, the odds of nonadherence were increased for blacks and Hispanics vs. whites and for younger ages vs. older; increased SLE-related comorbidities were associated with reduced odds of nonadherence for persistent nonadherers (0.95, 95% CI: 0.91-0.99).
Among HCQ initiators with SLE, we observed poor adherence which declined for most over the first year of use. HCQ adherence is a dynamic behavior and further studies of associated predictors, outcomes, and interventions should reflect this.
羟氯喹 (HCQ) 是大多数系统性红斑狼疮 (SLE) 患者的标准治疗药物,但普遍存在不遵医嘱的情况。我们调查了美国 SLE 队列中 HCQ 使用者的纵向不遵医嘱模式和预测因素。
我们使用来自 28 个州的医疗补助数据,确定了有 SLE 既往史的 18-65 岁成年人。我们纳入了在没有使用 HCQ 至少 6 个月后首次使用 HCQ 的患者,且在首次配药(索引日期)后需要至少 1 年的随访。我们使用比例用药天数(PDC)来描述整体 HCQ 用药依从性(<80%=不遵医嘱),并使用新型基于群组的轨迹模型(GBTM)来观察使用第一年的每月用药模式(<80%的天数/月覆盖=不遵医嘱)。使用多变量多项逻辑回归模型来检验不遵医嘱的预测因素。
我们确定了 10406 例有 SLE 的 HCQ 使用者。平均年龄为 38(±12)岁,94%为女性,42%为黑人,31%为白人;85%的患者 PDC<80%。在我们的 4 组 GBTM 中,17%的患者为持续依从者,36%为持续不依从者,47%形成两种部分依从的动态模式。大多数患者在第一年的依从性逐渐下降。与持续依从者相比,黑人、西班牙裔患者的不依从率高于白人患者,年轻患者的不依从率高于老年患者;与持续不依从者相比,伴有更多 SLE 相关合并症的患者不依从的可能性较低(0.95,95%CI:0.91-0.99)。
在有 SLE 的 HCQ 使用者中,我们观察到依从性差,且在使用的第一年大多数患者的依从性逐渐下降。HCQ 依从性是一种动态行为,进一步研究相关预测因素、结果和干预措施应该反映这一点。